netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 11: Eye - Full Chapter
11.08.02  Expand sub section  Ocular diagnostic and peri-operative preparations and photodynamic treatment
11.08.02  Expand sub section  Ocular diagnostic preparations
11.08.02  Expand sub section  Ocular peri-operative drugs
11.08.02  Expand sub section  Subfoveal choroidal neovascularisation
Aflibercept intraocular injection (Eylea)
(Ophthalmology)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultant Ophthalmologists ONLY
    • See links below
  • RFL:
    • As per NICE guidance
    • To be prescribed by consultant opthalmologists only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NCL JFC: Central Retinal Vein Occlusion (CRVO) Pathway
Link  NCL JFC: Wet Aged-Related Macular Degeneration (wAMD) Pathway
Link  NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Link  NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Link  NICE TA346: Aflibercept for treating diabetic macular oedema
Link  NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Link  NICE TA486: Aflibercept for treating choroidal neovascularisation
   
Ranibizumab intravitrial injection
(Ophthalmology)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultant Ophthalmologists ONLY
    • See links below
  • RFL:
    • Prior funding approval required. Restricted to Opthalmology.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Opthalmology
 
Link  NCL JFC: Diabetic Macular Oedema (DMO)
Link  NCL JFC: Branch Retinal Vein Occlusion (BRVO)
Link  NCL JFC: Central Retinal Vein Occlusion (CRVO)
Link  NCL JFC: Wet Aged-Related Macular Degeneration (wAMD)
Link  NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (wAMD)
Link  NICE TA274: Ranibizumab for treating diabetic macular oedema
Link  NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Link  NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
   
Verteporfin (Visudyne)
(Ophthalmology)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • Non-formulary.
  • RFL:
    • For PDT for wet AMD in line with NICE TA 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NICE TA68: Photodynamic therapy for age related macular degeneration
   
Bevacizumab intravitreal injection
View adult BNF View SPC online View childrens BNF
Unlicensed Drug Unlicensed
AAAAAAAA

Approved for:

  • Neovascular glaucoma (single-dose intravitreal) as an adjunct to panretinal photocoagulation (January 2017)
  • Pre-operative adjunct to diabetic vitrectomy (MEH only; April 2017)
  • Coats' disease and Familial exudative vitreoretinopathy (FEVR) (November 2015)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use in neovascular glaucoma as an adjunct to panretinal photocoagulation
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
 
   
11.08.02  Expand sub section  Vitreomacular traction to top
 ....
 Non Formulary Items
Pegaptanib Sodium  (Macugen)
(Ophthalmology)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

GP - 1st

Medicines suitable for first-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.

  

GP - 2nd

Medicines suitable for second-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.

  

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

  

GP - Grey

Medicines on hospital formularies which have not been reviewed for suitability in primary care.  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary